Email updates

Keep up to date with the latest news and content from Cell & Bioscience and BioMed Central.

This article is part of the series TGF-β signaling and biology .

Open Access Highly Accessed Review

Partners in crime: the TGFβ and MAPK pathways in cancer progression

Douglas A Chapnick1, Lisa Warner1, Jennifer Bernet2, Timsi Rao1 and Xuedong Liu1*

Author Affiliations

1 Department of Chemistry and Biochemistry and Molecular, Cellular and Developmental Biology

2 University of Colorado, Boulder, Colorado 80309, USA

For all author emails, please log on.

Cell & Bioscience 2011, 1:42  doi:10.1186/2045-3701-1-42


The electronic version of this article is the complete one and can be found online at: http://www.cellandbioscience.com/content/1/1/42


Received:10 November 2011
Accepted:28 December 2011
Published:28 December 2011

© 2011 Chapnick et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The TGFβ and Ras-MAPK pathways play critical roles in cell development and cell cycle regulation, as well as in tumor formation and metastasis. In the absence of cellular transformation, these pathways operate in opposition to one another, where TGFβ maintains an undifferentiated cell state and suppresses proliferation, while Ras-MAPK pathways promote proliferation, survival and differentiation. However, in colorectal and pancreatic cancers, the opposing pathways' mechanisms are simultaneously activated in order to promote cancer progression and metastasis. Here, we highlight the roles of the TGFβ and Ras-MAPK pathways in normal and malignant states, and provide an explanation for how the concomitant activation of these pathways drives tumor biology. Finally, we survey potential therapeutic targets in these pathways.

Keywords:
TGFβ; Metastasis; ERK; MEK; Ras; Crosstalk; Signal Transduction

Introduction

A cell must acquire several key characteristics in order to become cancerous: proliferation without limit in the absence of extracellular signals, resistance to apoptosis, evasion of anti-growth signals and immune destruction, as well as increased cellular motility [1,2]. The TGFβ and Ras-MAPK pathways have each been implicated in all of the cellular processes that a cancer cell must exploit on the path to malignancy. However, it is becoming increasingly clear that these pathways interact, such that the resulting signal crosstalk contributes largely to the acquisition of many of the key characteristics of a cancer cell.

The TGFβ signaling pathway regulates differentiation, migration, and death during normal development. Mutations to the TGFβ signaling pathway are commonly seen in many genetic diseases and cancers [3-5]. For example, early lesions in colorectal and pancreatic cancers frequently include mutations of the cell surface TGFβ receptors or Smad transcription factors. However, the role of the TGFβ ligand in cancer progression has been somewhat puzzling and paradoxical due to its multiple, often opposing, effects on cell growth. This TGFβ paradox is best exemplified by the fact that TGFβ has been shown to act not only as a tumor suppressor, but also as a promoter of tumor growth and metastasis [6,7].

Ras-MAPK signaling has been linked to fundamental cell processes such as differentiation, migration and proliferation [8,9]. The GTPase Ras and the Ras-MAPK cell surface receptors that initiate the intracellular signaling pathway (EGFR, FGFR, etc.) are often mutated in colorectal and pancreatic cancer, and these mutations lead to a constitutively active Ras-MAPK pathway [10]. Once commandeered, MAPK transcription factor substrates promote unchecked cellular proliferation, leading to tumor initiation. This review will examine the parallels between and intersections of these two pathways, with emphasis placed on their relevance in colorectal and pancreatic cancers. We will explore how the interactions between these pathways contribute to the physiological changes displayed by cancer cells, and how these interactions are modulated throughout tumor progression and metastasis.

The canonical Ras-MAPK pathway

The Ras-MAPK (Mitogen Activated Protein Kinase) pathway begins with growth factor binding to transmembrane Receptor Tyrosine Kinases (RTKs) (Figure 1). Growth factor binding initiates homodimerization and auto-phosphorylation in trans at specific tyrosines of the RTKs [10,11]. Growth factor receptor-bound protein 2 (Grb2) is then recruited to the cytosolic portion of the RTKs via a Src homology 2 (SH2) domain which binds to phosphotyrosines. Grb2 then recruits a guanine exchange factor, Son of Sevenless (SOS), via an SH3 domain and the GTPase Ras [10,11]. Ras, a protein that was originally identified as the transforming component in oncogenic viruses, is then post- translationally modified with an isoprenyl group that localizes it to the plasma membrane [2,12]. The GTPase activity of Ras is enhanced by the GTPase Activating Protein (GAP). Ras recruits and activates the MAPK kinase kinase (MAPKKK) Raf which initiates a phosphorylation cascade from Raf to MEK (MAPKK) which finally phosphorylates ERK (MAPK, Extracellar Regulated Kinase). Phosphorylated ERK then translocates to the nucleus where it phosphorylates transcription factors important for proliferation and differentiation [10,11].

thumbnailFigure 1. Schematic of the Ras-MAPK and TGFβ pathways. The left-hand side of the schematic depicts the Ras-MAPK pathway while the right-hand side of the schematic shows the Smad-dependent TGFβ signaling pathway. The details of both pathways are elaborated in the text. Both pathways begin with extracellular factor binding transmembrane cell surface receptors and end with transcriptional changes. Differences in the Ras-MAPK and TGFβ pathways are evident in the method by which stimulus signals are relayed to the nucleus. The Ras-MAPK pathway utilizes a phosphorylation cascade that results in signal amplification and a nonlinear switch-like response to stimulus. The TGFβ pathway is depicted here as a linear response to stimulus due to the direct interaction of transcription factor Smads with transmembrane receptors TGFβRI and TGFβRII. Box 1, 2 and 3 indicates points of integration that are detailed in the text.

The regulation of the activity and the specificity of MAPKs is critical for proper function and accurate transduction of extracellular signals. ERK is deactivated by MAPK phosphatases, resulting in a pathway that can terminate signaling in the absence of upstream stimuli [13]. The binding sites on ERK, auxiliary to the substrate recognition motif in the active site of ERK, confer the specificity for substrates [14]. Recent studies indicate that scaffolding proteins may play an important role in the timing and the amplitude of Ras-MAPK by regulating the location of MAPK components [15]. The scaffold either sequesters them to the cytosol and delays a response or facilitates a faster phopsphorylation cascade through the spatial concentration of the kinases (Figure 1), as has been shown for the scaffolding protein KSR (Kinase Supressor of Ras) [15,16].

The canonical TGFβ pathway

TGF-β signals through two receptor types, the TGF-β type I and type II receptors (TβRI and TβRII, respectively) [17]. Both receptors are Ser/Thr kinases. While the type II receptor is constitutively active, the type I receptor is inactive in the absence of ligand[18]. TGF-β can bind the type II receptor independent of the type I receptor [19]. Upon binding of the ligand, TGF-β induces oligomeric receptor complex formation which enables the type II receptor to phosphorylate the type I receptor in the GS domain and consequently cause a conformational change and release of inhibitory molecules such as FKBP12[18,20]. Activated TβRI recruits and phosphorylates Smad2 and Smad3 (R-Smads), a process that is aided by SARA (Smad Anchor for Receptor Activation)[21,22]. Phosphorylation of the R-Smads causes a conformational change such that the R-Smad is released from SARA [21]. Phosphorylated R-Smad binds Smad4 forming a R-Smad/Smad4 complex, as well as forming homo-oligomeric complexes, which translocate to the nucleus and directly interact with DNA, resulting in the recruitment of coactivators or chromatin remodeling components [23]. The recruitment of coactivators, corepressors and chromatin remodeling components determines the ultimate Smad dependent cellular response to the ligand stimulation [23]. TGF-ß regulates the transcript levels of approximately 100-300 genes in various cell types (Figure 1) [1-3].

The Non-canonical TGFβ pathway

Activation of Smads by TGF-ß is invariant in most cell types and therefore this pathway is known as the canonical TGF-ß pathway. Beside activation of Smads, TGF-ß also modulates the activity of several other signaling pathways in a ligand and receptor dependent manner (e.g. MAP kinase (MAPK) pathways, Rho-like GTPase signaling pathways, and phosphatidylinositol-3-kinase (PI3K)/AKT pathways [24-26]). Unlike the canonical pathway, modulation of these pathways by TGF-ß is often cell type specific and context dependent [27]. They are collectively referred to as non-Smad or noncanonical TGF-ß signaling pathways. Although canonical TGF-ß signaling through Smads dominated the field of TGF-ß research over the last decade, there has been increasing attention paid to the noncanonical TGF-ß signaling, particularly in the context of cell migration and epithelial-mesenchymal transition (EMT). In mammalian cells, all three MAPKs are activated by TGF-ß (Figure 1) (Each MAPK has different isoforms and, for simplicity, they are generically referred as Erk, JNK and p38). However, the kinetics of these activations vary with cell types and culture conditions [24-26,28,29]. The upstream signal transducers to MAPKs are likely small GTPases (Ras, Rac, RhoA and Cdc42) [24-26,29]. Their activities are frequently regulated by TGF-ß through diverse mechanisms. Here, we will focus on the Ras-MAPK pathways. For detailed discussions on the various noncanonical or non-Smad TGF-ß pathways, please refer to several excellent reviews on this topic [24-26,30].

It has been known for some time that TGF-ß rapidly activates Erk MAP kinases through Ras, but the magnitude of the resulting activation of Erk1/2 is much lower compared the activation by RTKs [28]. One mechanism that has been identified involves phosphorylation of ShcA by the TGFβ receptor complex on the tyrosine residues of ShcA. Similar to the RTK signaling, ShcA phoshotyrosines recruit the Grb2/SOS/Ras complex which subsequently trigger the activation of the Ras-MAPK pathway (Box 1, Figure 1) [31]. The biological significance of intrinsic activation of Ras-MAPK by TGFβ in normal cellular process is still poorly understood. Gene expression profiling studies implicate that TGF-β-stimulated Erk activation is involved in the modulating of a subset of genes that figure prominently in cell motility and cell-matrix interaction [32]. Some of the genes are often associated with epithelial to mesenchymal transition (EMT), an indispensable mechanism for producing mesenchymal cells, tissues and organs during normal development [33-35]. Thus, the intrinsic, relatively low, activation of Ras-MAPK is likely crucial for specific induction of genes regulating EMT and cellular motility.

Signaling Crosstalk Between the Ras-MAPK and TGFβ pathways

The integration of Ras-MAPK and TGFβ pathways can occur via balanced activation of both canonical and noncanonical TGFβ pathways by TGFβ alone, through simultaneous stimulation of TGFβ and ligands of other signaling pathways that modulate the activity of Ras-MAPK, or through crosstalk via interactions between the intracellular effector proteins distinct to each of the two pathways. In the two lattermost mechanisms, there are two common points of integration of the Ras-MAPK and TGFβ pathways: 1) phosphorylation of coactivators of R-Smads by Erks, 2) phosphorylation of Smad2/3 by Erks in the linker region. Most of the TGFβ signaling responses are cell context dependent [27]. The cell type specific responses are in part due to Smad interaction with cell type specific transcription factors [23]. For example, activated Smad3 binds its cognate sites with Oct4 in embryonic stem cells (ESCs), MyoD in myotubes and PU.1 in pro-B cells [23]. The association between activated Smad2/3 and transcriptional cofactors can be regulated by the Ras-MAPK pathway. For example, Ras-MAPK activity has been shown to regulate the interaction of p53 and Smad2/3. In this mechanism, FGF signals through Ras-MAPK to regulate p53 phosphorylation at its N-terminus (Ser6 and Ser9) by CK1 ∈/δ [36]. Such phosphorylation of p53 enables its interaction with activated Smad2/3 to regulate target genes that are important for TGFβ cytostatic program [36]. Similarly, Src-activated Epidermal Growth Factor Receptor (EGFR) signals through Ras-MAPK to engender phosphorylation of the E-box binding transcription factor USF and facilitate its interaction with activated Smad2/3 to regulate PAI-1 gene expression [37]. Thus, the RTK activated Ras-MAPK pathway converges with the canonical TGFβ pathway at chromatin in order to regulate gene expression.

Ras-MAPK has also been shown to phosphorylate R-Smads auxiliary to the activation regions[38,39], sequestering them to the cytoplasm to attenuate TGFβ signaling [39]. However, the opposite effect of activated Ras-MAPK on Smad activity has also been reported [40-42]. A possible explanation for the contradictory observations is that the levels of Ras activity could dictate the outcome of the experiment [43]. In a majority of human cancers carrying oncogenic Ras mutations, the activity rather than the levels of Ras expression is elevated. Thus, the levels of Ras activity translate into the levels of MAPK activity, ultimately shaping the TGFβ response via crosstalk between R-Smads and the Ras-MAPK pathway.

The linker region between Mad Homology Domains 1 and 2 (MH1 and MH2) have been shown to be phosphorylated by GSK-3 and ERK1/2. Phosphorylation of Ser204 on Smad3 via GSK-3 kinase activity results in decreased affinity between Smad3 and CREB binding protein, suggesting that the functional significance of the linker region phosphorylation status is to modulate transcription factor activity of SMAD proteins, rather than to regulate the nucleocytoplasmic localization of Smad proteins[44]. Consistent with this theory, the linker region phosphorylation of Smad2 and Smad3 by ERK1/2 at positions Ser240/Ser245/Ser250 and Ser204/Ser208/Ser215, respectively, has been shown to enhance Smad transcriptional activity of the Type I and Type III Collagen gene [40,45]. Additionally, Small C-terminal Phosphatase (SCPs) in the nucleus have been shown to dephosphorylate the linker region phosphorylation sites in Smad2, confirming a primarily nuclear role of the linker region phosphorylation [46]. Such dephosphorylation by SCPs results in activation of Smad dependent transcriptional regulation of exogenous luciferase reporters[46]. Thus, conflicting results about the functional consequences of linker region phosphorylation suggest that not only is Smad2/3 transcriptional activity regulated in a cell type specific manner, but also perhaps in a single cell type discrete genes are positively or negatively regulated by linker region phosphorylation in a chromatin context dependent manner.

Taken together, the current and previously reported data strongly suggests that different cellular responses to TGFβ stimulation in different cell types and cellular contexts largely results from the status of MAPK activity at the time of ligand stimulation.

Systems Features of MAPK and TGFβ pathways

Even though the signaling of the TGFβ and Ras-MAPK pathways initiates upon ligand binding at the plasma membrane, the modes of signal transmission are quite different [47,48]. The Ras-MAPK pathway features a cascade of sequential kinase phosphorylations/activations from RAF to ERK (Figure 1). This type of pathway architecture can lead to significant amplification of the original upstream receptor/ligand binding signal. The RTKs also activate other signaling pathways such as PLCγ, PI3K or Src. Some of these signaling pathways can feed into Ras-MAPK and produce positive feedback loops. There are also multiple well characterized negative feedback loops in the Ras-MAPK pathway that cause desensitization or dampening of the signal [49]. The presence of these feedback loops have been shown to produce switch-like (i.e. bistable) responses to receptor activation, allowing for a tight threshold of cellular response during development [50,51].

Unlike the Ras-MAPK pathway, the TGFβ signal relay system is relatively short. There are no apparent signal amplification steps in the signaling cascade subsequent to the receptor phosphorylation of R-Smads. The constant shuttling of Smads in and out of the nucleus allows the Smads to constantly monitor receptor activity [48]. This type of arrangement results in a more linear response to ligand binding. However, a more recent study reveals that TGFβ depletion during signaling is important to produce threshold-like input/output response to receptor activation [52]. Clearly, there is also nonlinearity in the TGFβ pathway.

Systems analysis of biological signaling pathways suggests that signaling pathways interact with one another and the final biological response is shaped by interaction between pathways [51]. Since there are multiple integration points between the Ras-MAPK and TGFβ pathways, it is not a surprise that the integration of these two pathways produces quite complex biological outcomes, depending on the cellular context. The challenge is how to precisely determine the behaviors of the interacting pathways and how to manipulate the end-point biological responses in normal and cancer cells.

Lesions in the Ras-MAPK and TGFβ pathways in Cancers

Colorectal and pancreatic cancers are, respectively, the fourth and fifth causes of cancer deaths [53]. More than one third of colorectal cancer patients develop metastasis. Of these cancers, about 35% are the result of genetic predisposition due to inherited lesions in the TGFβ pathway [54]. Additionally, mutations that inactivate the key signal components, including receptors and Smads, are frequently observed within the tumor. Loss of function mutations in TβRII have been found in a majority of colorectal and gastric carcinomas with microsatellite instability (MSI) [55,56]. In microsatellite stable colon cancer cell lines, missense mutations are identified in ~15% of cases [57]. Inactivating mutations of TβRI occurs at low frequency in pancreatic and biliary carcinomas [58] but relatively high in ovarian cancers with wild type TβRII [59]. In one example of TGFβ pathway lesion, TGFβRI*6A, the TGFβRI is missing three alanines from the signal sequence. TGFβRI*6A was previously associated with hereditary cancers based on analysis of a limited numbers of cases [60,61]. Recent work using a much larger number of case studies suggests that there is no increased hereditary risk of colon cancer associated with this mutation [62]. However, it is still possible that TGFβRI*6A does convey increased risk in specific patient populations or in somatic mutations [62].

Inactivation of TGF-β signaling also occurs by disabling Smad proteins. SMAD4 was originally identified as a tumor-suppressor gene lost in pancreatic cancers called DPC4 (deleted in pancreatic cancer 4) [63]. Subsequent studies revealed that deletion of Smad4 also occurs in 16-25% of colorectal cancer [64]. Germline mutations of SMAD4 are associated with juvenile polyposis and hamartomatous polyposis [65,66]. Inactivating mutations of Smad2 have been identified in ~6% of colorectal cancers while loss of function mutations of Smad3 are rare in colorectal cancers [64,67].

Escaping the TGFβ growth constraint is one of the hallmarks of tumor cells [2]. Tumor cells explore different mechanisms to achieve this. Despite the fact that inactivating mutations in the canonical TGFβ pathways in colorectal and pancreatic tumors are wide spread, cells isolated from other tumor types preserve the functionality of the canonical TGFβ signaling components and achieve TGFβ growth resistance by altering other aspects of the pathways [5]. Thus, oncogenic activation can also interdict TGFβ growth inhibitory responses by modifying the activity of downstream elements such as cell cycle inhibitors or transcriptional cofactors of Smad transcription factor activity.

Throughout tumor progression, the TGFβ ligand becomes highly expressed and actually promotes proliferation, particularly in the case of prostate cancer [68]. This may be due to its ability to stimulate MAPK pathways [69]. High levels of TGFβ are correlated with increased angiogenesis, as the tumor recruits blood vessels to allow for greater growth by inducing greater TGFβ dependent VEGF expression [70]. In the clinic, patients with high levels of TGFβ have decreased survival, likely due to aggressive tumor progression and metastasis [71]. In addition to over secretion of the TGFβ ligand, deregulation of the intracellular pathway can sensitize cells to an unchanging amount of TGFβ ligand. For example, in situ cell culture RNAi knockdown of Phosphatase and Tensin Homolog (PTEN), a TGFβR phosphatase, resulted in the increased TGFβ dependent invasion potential of cells [72]. Recent studies also suggest that TGFβ is involved, in some cell types, in directing metastatic cells to specific locations such as bone [73,74]. The cellular response to TGFβ in tumors clearly plays a role in tumor metastasis, even though there is not strong evidence that R-Smads mediate this role.

The Ras-MAPK pathway is an important component of many cancerous cells. The majority of cancer associated lesions to the Ras-MAPK pathway result in constitutive activation of the pathway [12]. Mutations that have been identified are located early in the pathway and include overexpression of RTKs, activating mutations to RTKs, sustained expression of activating autocrine or paracrine ligands, and mutations to Ras and Raf [2,12]. Temporally, these lesions occur early in tumorigenesis and are sustained for the life of the cancer (Figure 2). Ras mutations have been found in 30% of all cancers, 90% of pancreatic cancers and 50% of colon cancers [12]. B-Raf mutations have been found in 65% of melanomas, 45% of papillary thyroid cancers and 36% of ovarian cancer [75-77]. In summary, a large portion of human tumors have a constitutively active Ras-MAPK pathway and have acquired resistance to TGFβ induced cell cycle arrest. Thus, the role of TGFβ in cancer progression seems to be largely through lesions that stimulate the non-cannonical signaling, and are aided by inactivating lesions in the canonical pathway, which are associated with cell-cycle arrest and the apoptotic response.

thumbnailFigure 2. Schematic showing the transitions from healthy to metastatic cells and the corresponding changes to TGFβ and MAPK signaling.

Crosstalk between TGFβ and Ras-MAPK Signaling Pathways drives EMT

Crosstalk between the TGFβ and Ras-MAPK pathways appears to be required for tumor metastasis, likely through the role of crosstalk in epithelial-mesenchymal transition (EMT). TGFβ induced EMT, which is a fundamental mechanism that drives metastasis in vivo or invasion in vitro, requires constant TGFβ signaling to become a stable phenotype [78,79]. The connection between EMT and metastasis is exemplified through the finding that fibroblast cells that undergo EMT are more conducive to promote tumor invasion [80]. EMT is marked by changes to the actin cytoskeleton, loss of cell polarity, and migration/invasion [35,81]. Acting alone, neither pathway is successful in permanently converting from an epithelial to a mesenchymal phenotype [41]. Long-term expression and cooperation of TGFβ and Ras- MAPK causes full EMT through induction of cytokine feedback loops that include upregulating TGFβ autocrine signaling [78]. Recently, a new mechanism by which TGFβ induces EMT has been introduced, where TGFβ induces isoform switching of fibroblast growth factor (FGF) receptors [80]. Prolonged treatment of TGFβ results in increased FGFR1IIIc, which is the mesenchymal isoform, and decreased expression of the epithelial isoforms of FGF receptors. FGF-2 but not FGF-7 signals through FGFR1IIIc[80]. The switch in FGF-2 receptor expression enables cells to respond to FGF-2 to activate Ras-MAPK. Furthermore, epithelial cells treated with both TGFβ and FGF-2 undergo EMT instead of epithelial to epithelial-myofibroblastic transition (EMyoT). Thus, the crosstalk between the Ras-MAPK and TGFβ pathways may be harnessed to promote tumor growth through EMT.

Conclusions and Future Directions

Colorectal and pancreatic cancers account for a large portion of cancer incidence and fatalities in the United States. Thus, they are important models for the study of the complicated roles of Ras-MAPK and TGFβ pathways. As more is learned about these pathways in normal and cancerous cells, it becomes increasingly clear that crosstalk between the distinct pathway components are important for TGFβ signal interpretation in a cell type and cell context dependent manner. Future studies are required to address the interdependency of these pathways, paying close attention to the connection between the cellular context in a study, the level of contribution of the Ras-MAPK pathway to the TGFβ response, and the ultimate cellular response to TGFβ ligand stimulation.

A consequence of this emerging theme of crosstalk may be the reevaluation of cancer therapeutic strategies. Currently, Ras and Raf have been the hot targets in the Ras-MAPK pathway for anticancer drugs. Inhibition of isoprenylation of Ras seemed promising. However, it appears that the enzymes that catalyze this reaction are somewhat promiscuous and off-target effects have limited the successful development of inhibitors of Ras. Other Ras-MAPK components such as Raf, MEK and ERK are also being investigated and are proving more successful drug targets [82]. One drug targeting Raf has been approved by the FDA for treatment of renal cell carcinoma and a handful of other drugs are in Phase I/II/III trials that target Raf and MEK [82]. TGFβ's involvement in promoting a metastatic phenotype in aggressive cancers makes it a highly sought after pathway to target for anticancer therapies. The obvious targets of choice are the TGFβ ligand itself, the ligand- binding surface on TGFβRI/II and betaglycan [83]. As a result, a humanized anti- TGFβ monoclonal antibody (GC1008) is in Phase I/II clinical trials. Additionally, soluble TGFβRII and betaglycan recombinant receptors, which compete for extracellular TGFβ, as well as inhibitors TGFβRI kinase activity have shown encouraging anti-metastatic results [84]. As might be the case for many kinase inhibitors, long term administration of a single agent may select for more aggressive drug resistant tumor variants, as has been demonstrated for LY2109761, a TβRI/TβRII kinase inhibitor in a mouse skin model [85]. Considering the synergistic effects of TGFβ and MAPK pathways in tumorigenesis it is logical to try a combinatorial approach in cancer treatments, where simultaneous partial inhibition of the Ras-MAPK and TGFβ pathways, yields synergistic inhibition of TGFβ ligand induced metatstasis, while having minimal impact on other aspects of TGFβ and Ras-MAPK biology.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

DAC and XL wrote and edited the article. DAC and XL designed Figure 1. LW, JB and TR designed Figure 2 and wrote the initial summary and portions of the article. DAC and XL compile the final references. All authors read and approved the final manuscript

Acknowledgements

DAC, LW and TR were supported by a predoctoral training grant from NIGMS (T32GM08759). Research in the Liu laboratory on TGFβ is supported by a National Institutes of Health grant (GM083172).

References

  1. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation.

    Cell 2011, 144(5):646-74. PubMed Abstract | Publisher Full Text OpenURL

  2. Hanahan D, Weinberg RA: The hallmarks of cancer.

    Cell 2000, 100(1):57-70. PubMed Abstract | Publisher Full Text OpenURL

  3. Massague J: TGFbeta in Cancer.

    Cell 2008, 134(2):215-30. PubMed Abstract | Publisher Full Text OpenURL

  4. Massague J, Blain SW, Lo RS: TGFbeta signaling in growth control, cancer, and heritable disorders.

    Cell 2000, 103(2):295-309. PubMed Abstract | Publisher Full Text OpenURL

  5. Akhurst RJ, Derynck R: TGF-beta signaling in cancer--a double-edged sword.

    Trends Cell Biol 2001, 11(11):S44-51. PubMed Abstract | Publisher Full Text OpenURL

  6. Roberts AB, Wakefield LM: The two faces of transforming growth factor beta in carcinogenesis.

    Proc Natl Acad Sci USA 2003, 100(15):8621-8623. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  7. Derynck R, Akhurst RJ, Balmain A: TGF-beta signaling in tumor suppression and cancer progression.

    Nat Genet 2001, 29(2):117-29. PubMed Abstract | Publisher Full Text OpenURL

  8. Robinson MJ, Cobb MH: Mitogen-activated protein kinase pathways.

    Curr Opin Cell Biol 1997, 9(2):180-6. PubMed Abstract | Publisher Full Text OpenURL

  9. Chang L, Karin M: Mammalian MAP kinase signalling cascades.

    Nature 2001, 410(6824):37-40. PubMed Abstract | Publisher Full Text OpenURL

  10. McKay MM, Morrison DK: Integrating signals from RTKs to ERK/MAPK.

    Oncogene 2007, 26(22):3113-21. PubMed Abstract | Publisher Full Text OpenURL

  11. van der Geer P, Hunter T, Lindberg RA: Receptor protein-tyrosine kinases and their signal transduction pathways.

    Annu Rev Cell Biol 1994, 10:251-337. PubMed Abstract | Publisher Full Text OpenURL

  12. Friday BB, Adjei AA: Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.

    Clin Cancer Res 2008, 14(2):342-346. PubMed Abstract | Publisher Full Text OpenURL

  13. Bhalla US, Ram PT, Iyengar R: MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network.

    Science 2002, 297(5583):1018-23. PubMed Abstract | Publisher Full Text OpenURL

  14. Biondi RM, Nebreda AR: Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions.

    Biochem J 2003, 372(Pt 1):1-13. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  15. White MA, Anderson RG: Signaling networks in living cells.

    Annu Rev Pharmacol Toxicol 2005, 45:587-603. PubMed Abstract | Publisher Full Text OpenURL

  16. Nguyen A, et al.: Kinase suppressor of Ras (KSR) is a scaffold which facilitates mitogen-activated protein kinase activation in vivo.

    Mol Cell Biol 2002, 22(9):3035-3045. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  17. Massague J: TGF-beta signal transduction.

    Annu Rev Biochem 1998, 67:753-91. PubMed Abstract | Publisher Full Text OpenURL

  18. Wrana JL, et al.: Mechanism of activation of the TGF-beta receptor.

    Nature 1994, 370(6488):341-347. PubMed Abstract | Publisher Full Text OpenURL

  19. Laiho M, Weis MB, Massague J: Concomitant loss of transforming growth factor (TGF)-beta receptor types I and II in TGF-beta-resistant cell mutants implicates both receptor types in signal transduction.

    J Biol Chem 1990, 265(30):18518-24. PubMed Abstract | Publisher Full Text OpenURL

  20. Chen YG, Liu F, Massague J: Mechanism of TGFbeta receptor inhibition by FKBP12.

    Embo J 1997, 16(13):3866-76. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  21. Shi Y, Massague J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus.

    Cell 2003, 113(6):685-700. PubMed Abstract | Publisher Full Text OpenURL

  22. Tsukazaki T, et al.: SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor.

    Cell 1998, 95(6):779-91. PubMed Abstract | Publisher Full Text OpenURL

  23. Mullen AC, et al.: Master Transcription Factors Determine Cell-Type-Specific Responses to TGF-beta Signaling.

    Cell 2011, 147(3):565-76. PubMed Abstract | Publisher Full Text OpenURL

  24. Moustakas A, Heldin C-H: Non-Smad TGF-beta signals.

    J Cell Sci 2005, 118(Pt 16):3573-3584. PubMed Abstract | Publisher Full Text OpenURL

  25. Mu Y, Gudey SK, Landstrom M: Non-Smad signaling pathways.

    Cell Tissue Res 2011. OpenURL

  26. Zhang YE: Non-Smad pathways in TGF-beta signaling.

    Cell Res 2009, 19(1):128-39. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  27. Ikushima H, Miyazono K: Cellular context-dependent "colors" of transforming growth factor-beta signaling.

    Cancer Sci 2010, 101(2):306-12. PubMed Abstract | Publisher Full Text OpenURL

  28. Mulder KM: Role of Ras and Mapks in TGFbeta signaling.

    Cytokine Growth Factor Rev 2000, 11(1-2):23-35. PubMed Abstract | Publisher Full Text OpenURL

  29. Giehl K, Imamichi Y, Menke A: Smad4-independent TGF-beta signaling in tumor cell migration.

    Cells Tissues Organs 2007, 185(1-3):123-30. PubMed Abstract | Publisher Full Text OpenURL

  30. Parvani JG, Taylor MA, Schiemann WP: Noncanonical TGF-beta signaling during mammary tumorigenesis.

    J Mammary Gland Biol Neoplasia 2011, 16(2):127-46. PubMed Abstract | Publisher Full Text OpenURL

  31. Lee MK, et al.: TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA.

    EMBO J 2007, 26(17):3957-67. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  32. Zavadil J, et al.: Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta.

    Proc Natl Acad Sci USA 2001, 98(12):6686-6691. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  33. Thiery JP, Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions.

    Nat Rev Mol Cell Biol 2006, 7(2):131-42. PubMed Abstract | Publisher Full Text OpenURL

  34. Sleeman JP, Thiery JP: SnapShot: The epithelial-mesenchymal transition.

    Cell 2011, 145(1):162 e1. PubMed Abstract | Publisher Full Text OpenURL

  35. Zavadil J, Bottinger EP: TGF-beta and epithelial-to-mesenchymal transitions.

    Oncogene 2005, 24(37):5764-74. PubMed Abstract | Publisher Full Text OpenURL

  36. Cordenonsi M, et al.: Integration of TGF-beta and Ras/MAPK signaling through p53 phosphorylation.

    Science 2007, 315(5813):840-3. PubMed Abstract | Publisher Full Text OpenURL

  37. Samarakoon R, Higgins PJ: Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells.

    Thromb Haemost 2008, 100(6):976-83. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  38. Matsuura I, et al.: Identification and characterization of ERK MAP kinase phosphorylation sites in Smad3.

    Biochemistry 2005, 44(37):12546-53. PubMed Abstract | Publisher Full Text OpenURL

  39. Kretzschmar M, et al.: A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras.

    Genes Dev 1999, 13(7):804-16. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  40. Hayashida T, Decaestecker M, Schnaper HW: Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells.

    FASEB J 2003, 17(11):1576-8. PubMed Abstract | Publisher Full Text OpenURL

  41. Janda E, et al.: Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways.

    J Cell Biol 2002, 156(2):299-313. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  42. Funaba M, Zimmerman CM, Mathews LS: Modulation of Smad2-mediated signaling by extracellular signal-regulated kinase.

    J Biol Chem 2002, 277(44):41361-8. PubMed Abstract | Publisher Full Text OpenURL

  43. Kfir S, et al.: Pathway- and expression level-dependent effects of oncogenic N-Ras: p27(Kip1) mislocalization by the Ral-GEF pathway and Erk-mediated interference with Smad signaling.

    Mol Cell Biol 2005, 25(18):8239-50. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  44. Millet C, et al.: A negative feedback control of transforming growth factor-beta signaling by glycogen synthase kinase 3-mediated Smad3 linker phosphorylation at Ser-204.

    J Biol Chem 2009, 284(30):19808-16. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  45. Li F, et al.: The linker region of Smad2 mediates TGF-beta-dependent ERK2-induced collagen synthesis.

    Biochem Biophys Res Commun 2009, 386(2):289-93. PubMed Abstract | Publisher Full Text OpenURL

  46. Wrighton KH, et al.: Small C-terminal domain phosphatases dephosphorylate the regulatory linker regions of Smad2 and Smad3 to enhance transforming growth factor-beta signaling.

    J Biol Chem 2006, 281(50):38365-75. PubMed Abstract | Publisher Full Text OpenURL

  47. Clarke DC, Liu X: Decoding the quantitative nature of TGF-beta/Smad signaling.

    Trends Cell Biol 2008, 18(9):430-42. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  48. Schmierer B, Hill CS: TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility.

    Nat Rev Mol Cell Biol 2007, 8(12):970-982. PubMed Abstract | Publisher Full Text OpenURL

  49. Sturm OE, et al.: The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier.

    Sci Signal 2010, 3(153):ra90. PubMed Abstract | Publisher Full Text OpenURL

  50. Ferrell JE Jr: Tripping the switch fantastic: how a protein kinase cascade can convert graded inputs into switch-like outputs.

    Trends Biochem Sci 1996, 21(12):460-6. PubMed Abstract | Publisher Full Text OpenURL

  51. Bhalla US, Iyengar R: Emergent properties of networks of biological signaling pathways.

    Science 1999, 283(5400):381-7. PubMed Abstract | Publisher Full Text OpenURL

  52. Zi Z, et al.: Quantitative analysis of transient and sustained transforming growth factor-beta signaling dynamics.

    Mol Syst Biol 2011, 7:492. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  53. Jemal A, et al.: Cancer statistics, 2010.

    CA Cancer J Clin 2010, 60(5):277-300. PubMed Abstract | Publisher Full Text OpenURL

  54. Xu Y, Pasche B: TGF-beta signaling alterations and susceptibility to colorectal cancer.

    Hum Mol Genet 2007, 16(Spec No 1):14-20. OpenURL

  55. Markowitz S, et al.: Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.

    Science 1995, 268(5215):1336-8. PubMed Abstract | Publisher Full Text OpenURL

  56. Ogino S, et al.: TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.

    Hum Pathol 2007, 38(4):614-20. PubMed Abstract | Publisher Full Text OpenURL

  57. Grady WM, et al.: Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers.

    Cancer Res 1999, 59(2):320-4. PubMed Abstract | Publisher Full Text OpenURL

  58. Goggins M, et al.: Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.

    Cancer Res 1998, 58(23):5329-32. PubMed Abstract | Publisher Full Text OpenURL

  59. Wang D, et al.: Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.

    Cancer Res 2000, 60(16):4507-12. PubMed Abstract | Publisher Full Text OpenURL

  60. Pasche B, et al.: TbetaR-I(6A) is a candidate tumor susceptibility allele.

    Cancer Res 1999, 59(22):5678-82. PubMed Abstract | Publisher Full Text OpenURL

  61. Bian Y, et al.: TGFBR1*6A may contribute to hereditary colorectal cancer.

    J Clin Oncol 2005, 23(13):3074-3078. PubMed Abstract | Publisher Full Text OpenURL

  62. Skoglund J, et al.: Lack of an association between the TGFBR1*6A variant and colorectal cancer risk.

    Clin Cancer Res 2007, 13(12):3748-3752. PubMed Abstract | Publisher Full Text OpenURL

  63. Hahn SA, et al.: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.

    Science 1996, 271(5247):350-3. PubMed Abstract | Publisher Full Text OpenURL

  64. Takayama T, et al.: Colorectal cancer: genetics of development and metastasis.

    J Gastroenterol 2006, 41(3):185-92. PubMed Abstract | Publisher Full Text OpenURL

  65. Howe JR, et al.: Common deletion of SMAD4 in juvenile polyposis is a mutational hotspot.

    Am J Hum Genet 2002, 70(5):1357-1362. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  66. Sweet K, et al.: Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis.

    JAMA 2005, 294(19):2465-73. PubMed Abstract | Publisher Full Text OpenURL

  67. Ku J-L, et al.: Genetic alterations of the TGF-beta signaling pathway in colorectal cancer cell lines: a novel mutation in Smad3 associated with the inactivation of TGF-beta-induced transcriptional activation.

    Cancer Lett 2007, 247(2):283-292. PubMed Abstract | Publisher Full Text OpenURL

  68. Bello-DeOcampo D, Tindall DJ: TGF-betal/Smad signaling in prostate cancer.

    Curr Drug Targets 2003, 4(3):197-207. PubMed Abstract | Publisher Full Text OpenURL

  69. de Caestecker MP, Piek E, Roberts AB: Role of transforming growth factor-beta signaling in cancer.

    J Natl Cancer Inst 2000, 92(17):1388-1402. PubMed Abstract | Publisher Full Text OpenURL

  70. Teraoka H, et al.: Enhanced VEGF production and decreased immunogenicity induced by TGF-beta 1 promote liver metastasis of pancreatic cancer.

    Br J Cancer 2001, 85(4):612-617. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  71. Friedman E, et al.: High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer.

    Cancer Epidemiol Biomarkers Prev 1995, 4(5):549-554. PubMed Abstract | Publisher Full Text OpenURL

  72. Hjelmeland AB, et al.: Loss of phosphatase and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activity.

    Cancer Res 2005, 65(24):11276-11281. PubMed Abstract | Publisher Full Text OpenURL

  73. Kakonen S-M, et al.: Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways.

    J Biol Chem 2002, 277(27):24571-24578. PubMed Abstract | Publisher Full Text OpenURL

  74. Kang Y, et al.: A multigenic program mediating breast cancer metastasis to bone.

    Cancer Cell 2003, 3(6):537-49. PubMed Abstract | Publisher Full Text OpenURL

  75. Xing M: BRAF mutation in thyroid cancer.

    Endocr Relat Cancer 2005, 12(2):245-262. PubMed Abstract | Publisher Full Text OpenURL

  76. Sieben NLG, et al.: In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.

    J Pathol 2004, 202(3):336-340. PubMed Abstract | Publisher Full Text OpenURL

  77. Brose MS, et al.: BRAF and RAS mutations in human lung cancer and melanoma.

    Cancer Res 2002, 62(23):6997-7000. PubMed Abstract | Publisher Full Text OpenURL

  78. Oft M, et al.: TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells.

    Genes Dev 1996, 10(19):2462-2477. PubMed Abstract | Publisher Full Text OpenURL

  79. Yu L, Hebert MC, Zhang YE: TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses.

    Embo J 2002, 21(14):3749-59. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  80. Shirakihara T, et al.: TGF-beta regulates isoform switching of FGF receptors and epithelial-mesenchymal transition.

    EMBO J 2011, 30(4):783-95. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  81. Huber MA, Kraut N, Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression.

    Curr Opin Cell Biol 2005, 17(5):548-558. PubMed Abstract | Publisher Full Text OpenURL

  82. Roberts PJ, Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.

    Oncogene 2007, 26(22):3291-3310. PubMed Abstract | Publisher Full Text OpenURL

  83. Yingling JM, Blanchard KL, Sawyer JS: Development of TGF-beta signalling inhibitors for cancer therapy.

    Nat Rev Drug Discov 2004, 3(12):1011-1022. PubMed Abstract | Publisher Full Text OpenURL

  84. Arteaga CL: Inhibition of TGFbeta signaling in cancer therapy.

    Curr Opin Genet Dev 2006, 16(1):30-37. PubMed Abstract | Publisher Full Text OpenURL

  85. Connolly EC, et al.: Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TbetaRI/II kinase inhibition with LY2109761.

    Cancer Res 2011, 71(6):2339-49. PubMed Abstract | Publisher Full Text OpenURL